Comparative Pharmacology
Head-to-head clinical analysis: MODAFINIL versus QUILLIVANT XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MODAFINIL versus QUILLIVANT XR.
MODAFINIL vs QUILLIVANT XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The precise mechanism of action is unknown. Modafinil is a wakefulness-promoting agent that may have direct or indirect effects on dopamine, norepinephrine, serotonin, GABA, glutamate, and orexin systems. It binds to the dopamine transporter and inhibits dopamine reuptake.
Extended-release oral suspension formulation of methylphenidate, a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their synaptic concentrations. The exact therapeutic effect in ADHD is unknown but is thought to involve dopaminergic and noradrenergic pathways in the prefrontal cortex.
200 mg orally once daily in the morning.
Initial: 25 mg orally once daily in the morning; may increase weekly in 25 mg increments based on tolerability and response. Maximum: 75 mg once daily.
None Documented
None Documented
Clinical Note
moderateArmodafinil + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Armodafinil."
Clinical Note
moderateModafinil + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Modafinil."
Clinical Note
moderateModafinil + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Modafinil."
Clinical Note
moderateModafinil + Erythromycin
Terminal elimination half-life is approximately 15 hours (range 10–30 hours). This supports once-daily dosing for sustained wakefulness.
Approximately 4 hours; extended-release formulation provides therapeutic levels for ~12 hours.
Primarily renal (as metabolites and unchanged drug); approximately 80% of the dose is recovered in urine, with less than 10% as unchanged modafinil. Fecal excretion accounts for less than 1%.
Primarily renal (approximately 60% as unchanged drug); fecal excretion accounts for <5%.
Category C
Category C
CNS Stimulant
CNS Stimulant
"The metabolism of Erythromycin can be decreased when combined with Modafinil."